Agaricus blazei (Royal Sun Mushroom) and bowel disease
What 2 graded rows on agaricus blazei (royal sun mushroom) agree on for bowel disease, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Agaricus blazei (Royal Sun Mushroom) page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Agaricus blazei (Royal Sun Mushroom) page, with its PubMed record.
Your question
Agaricus blazei (Royal Sun Mushroom) and bowel disease
2 rows · 100 peopleSplit. 1 row found an improvement and 1 found no difference.
- DGrade D× 1
- ∅No effect× 1
- Rows
- 2
- Trials
- 2
- People
- 100
Where they differ
From the rowsThe best-graded row, grade D, is a randomized trial of 50 people (2016) and found an improvement. 1 row is graded No effect, our grade for adequately powered trials that found no effect.
By our six checks (size, design, length, who was studied, year and grade), the two sides do not differ cleanly. The dose and how each outcome was measured are in the rows below.
The rows
1 improved · 1 no difference- DGrade DSymptoms, fatigue and quality of life in ulcerative colitis · Improved
RCT · n 50 · 2016 · Adults in Norway with symptomatic ulcerative colitis
60 mL a day · 21 days
Symptom scores fell from 5.88 to 4.50 (p = 0.001) and fatigue improved with AndoSan but not placebo; between-group models favored AndoSan. Fecal calprotectin did not change.
Row on the Agaricus blazei (Royal Sun Mushroom) page · PubMed 26933886 (opens PubMed)
- ∅No effectSymptoms, fatigue and quality of life in Crohn's disease · No difference
RCT · n 50 · 2016 · Adults in Norway with symptomatic Crohn's disease
30 mL twice a day (full text) · 21 days
Symptoms improved from baseline with AndoSan, but there was no significant difference between groups (p = 0.106); fatigue improved similarly in both.
Row on the Agaricus blazei (Royal Sun Mushroom) page · PubMed 27415795 (opens PubMed)